Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Chi

Showing results (101-110 of 410) with videos related to

Pageof 41
Sort By:
The Journal of Biological Chemistry|April 2, 2010
The plastic energy landscape of protein folding: a triangular folding mechanism with an equilibrium intermediate for a small protein domainS Raza Haq, Maike C Jürgens, Celestine N Chi, et al.
Biochemistry|October 11, 2012
Interactions outside the boundaries of the canonical binding groove of a PDZ domain influence ligand bindingCelestine N Chi, S Raza Haq, Serena Rinaldo, et al.
Investigational New Drugs|August 28, 2016
Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC)Sunil Parimi, Misha Eliasziw, Scott North, et al.
The Chinese Journal of Physiology|July 1, 2022
The role of pleural fluid lactate dehydrogenase-to-adenosine deaminase ratio in differentiating the etiology of pleural effusionsChun-Yee Ho, Yu-Hui Tsai, Chih-Chun Chang, et al.
Molecular Oncology|February 5, 2013
Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): favorable activity of targeting EGFR- ErbB2 signaling with lapatinibAnjali Singh, Xueqing Lun, Aarthi Jayanthan, et al.
Science Advances|November 7, 2018
Structure and dynamics conspire in the evolution of affinity between intrinsically disordered proteinsPer Jemth, Elin Karlsson, Beat Vögeli, et al.
European Review for Medical and Pharmacological Sciences|January 4, 2022
LINC00261 regulates EBF1 to suppress malignant progression of thyroid cancerX-D Fu, C-Y Liu, Y-L Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2012
A phase II pharmacodynamic study of preoperative figitumumab in patients with localized prostate cancerKim N Chi, Martin E Gleave, Ladan Fazli, et al.
Investigational New Drugs|July 26, 2011
A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancerEmma K Beardsley, Sebastien J Hotte, Scott North, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2005
Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancerBernhard J C Eigl, Scott E Eggener, Jenny Baybik, et al.
Pageof 41

Showing results (101-110 of 410) with videos related to

Sort By:
Pageof 41
The Journal of Biological Chemistry|April 2, 2010
The plastic energy landscape of protein folding: a triangular folding mechanism with an equilibrium intermediate for a small protein domainS Raza Haq, Maike C Jürgens, Celestine N Chi, et al.
Biochemistry|October 11, 2012
Interactions outside the boundaries of the canonical binding groove of a PDZ domain influence ligand bindingCelestine N Chi, S Raza Haq, Serena Rinaldo, et al.
Investigational New Drugs|August 28, 2016
Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC)Sunil Parimi, Misha Eliasziw, Scott North, et al.
The Chinese Journal of Physiology|July 1, 2022
The role of pleural fluid lactate dehydrogenase-to-adenosine deaminase ratio in differentiating the etiology of pleural effusionsChun-Yee Ho, Yu-Hui Tsai, Chih-Chun Chang, et al.
Molecular Oncology|February 5, 2013
Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): favorable activity of targeting EGFR- ErbB2 signaling with lapatinibAnjali Singh, Xueqing Lun, Aarthi Jayanthan, et al.
Science Advances|November 7, 2018
Structure and dynamics conspire in the evolution of affinity between intrinsically disordered proteinsPer Jemth, Elin Karlsson, Beat Vögeli, et al.
European Review for Medical and Pharmacological Sciences|January 4, 2022
LINC00261 regulates EBF1 to suppress malignant progression of thyroid cancerX-D Fu, C-Y Liu, Y-L Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2012
A phase II pharmacodynamic study of preoperative figitumumab in patients with localized prostate cancerKim N Chi, Martin E Gleave, Ladan Fazli, et al.
Investigational New Drugs|July 26, 2011
A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancerEmma K Beardsley, Sebastien J Hotte, Scott North, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2005
Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancerBernhard J C Eigl, Scott E Eggener, Jenny Baybik, et al.
Pageof 41